U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07441395) titled 'Phase 2 Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD' on Feb. 23.
Brief Summary: The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study.
The study doctors will see how safe soquelitinib is by tracking side effects among participants. They will also check "tolerability," which means how well the participants can handle soquelitinib and whether any potenti...